Hints to how they will Utilize Lung Cancer as their Core and Use the Same Therapy for COVID-19 patients as it treats Inflammation in which the corona virus attacks the LUNGS... NSPX has Mipsagargin which is a New alternative drug to help COVID-19 patients as need it to treat the LUNGS!!!
(MOST RECENTLY AS OF April 7th 2020 look at who part of this!) BOTANICAL AND PLANT-DERIVED DRUGS MARKET 2020 | BY TRENDING MANUFACTURERS | BY REGIONS | BY TYPES AND APPLICATIONS, FORECASTS TO 2026
The final report will add the analysis of the Impact of Covid-19 in this report Botanical and Plant-derived Drugs industry.
Phyton is converting the Thapsia plant into thapsigargin in partnership with Inspyr Therapeutics, Inc. (OTCQB: NSPX), a clinical-stage biotechnology company that has a patented technology platform utilizing thapsigargin for its prodrug delivery system, mipsagargin.
A possible partnership could be in the making through Phyton Biotech IMO, they work with a lot of big Pharma players and this company is an expert in the field thanks to their Plant Cell Fermentation Technology.
Smells like someone who wants to either a Reverse MERGER, a Partnership or BUYOUT is in the works and needs NSPX to be updated with what they have in thier CORE ...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.